Retatrutide vs Glucagon: In-Depth Analysis of Peptide Product Composition
Abstract: Retatrutide, a novel triple agonist (GIP/GLP-1/glucagon), contrasts sharply with standalone glucagon peptides in composition and therapeutic scope. Market trends show retatrutide dominating obesity and NASH pipelines, while glucagon remains critical for hypoglycemia. Product comparison reveals retatrutide’s superior metabolic efficacy but higher complexity and cost. Brand analysis highlights Eli Lilly’s leadership; glucagon products (e.g., Novo Nordisk) offer established safety profiles. Technical advantages of retatrutide include multi-receptor synergy; disadvantages include injection site reactions. Parameter data (half-life, receptor affinity) and logistics (cold chain) are critical for selection. Industry outlook favors multi-agonists, with regulatory certifications (GMP, USP) essential for quality assurance.